The Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality ...

Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030Ramat Gan, Israel, Feb. 18, 2025 (GLOBE ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.08. Operator: Good morning, ladies and gentlemen, and welcome to ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

JENA, Germany - InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company focusing on anti-inflammatory therapeutics, has initiated a public offering of its ordinary shares along with pre-funded ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

Millions of South Africa are suffering with symptoms generally known as Long Covid. This growing crisis is shattering lives, ...

In the Q4 earnings call, the company stated that it has focused its R&D portfolio on four key therapeutic areas: oncology, ...

To date, 14 patients have now been enrolled in the expanded access program. The first 10 patients have all shown either an improvement or stability of disease within 6 months ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...